Titasville (Florida): Every astronaut in the self-proclaimed-mission (AX-4), including India’s group captain Shubanshu Shukla, is contributing to its earlier medical study-a experiment called a suit ride-which can redefine to go into space. While TOI broke the story in March, now more details have emerged from a special interview with Mohammad Fighton, clinical lead for the Suit ride experiment And Chief Medical Officer in Burjel Medical City.He said that the crew is central to validate new techniques which can allow even a day permission. Insulin -dependent diabetes To fly safely. “Currently, astronauts with diabetes, especially people requiring insulin, are excluded from the spaceflight. This study is doing the ground task to change it,” said Dr. Fitian. The suite ride experiment, which has been developed in collaboration between Burjel Holdings and Ex -Space, focuses on monitoring how glucose behaves in microgravity and what insulin remains stable during space missions. None of the four astronauts aboard in the AX-4 have diabetes, but each has conducted pre-oblique tests to install individual glucose baseline on Earth. “They act as healthy controls. It allows us to compare data from space against ground-based measures, which is important to validate the credibility of continuous glucose monitors (CGMs) in the classroom,” said Dr. Fitian.At least one astronaut will wear a CGM (Continuous glucose monitoring) The device throughout the mission was sent back to the research team with real -time metabolic data. In addition, insulin pen-although not used by the crew, is flown to test how the compound behaves when exposed to space conditions. The samples stored at the environment and refrigerated temperatures will be analyzed to investigate the decline after the flight.“Micogravity gives us the opportunity to inspect metabolic functions without gravity, asanas and confused factors of muscle use,” said Dr. Fitian. It makes it easy to separate how hormones and cells regulate glucose and reveal early signs of insulin resistance that are difficult to detect on Earth.Results, according to them, can eventually affect medical protocols for long -term missions. “If this technique proves to be accurate and stable, the boycott of insulin-credited diabetics can be reconsidered. This will be one step ahead to make the spaceflight more inclusive.”There are also terrestrial benefits of suite rides. This sourter can lead to more effective insulin therapy for people in glucose glucose monitoring tools and more effective insulin therapy especially in remote or resource-limited settings on Earth. Technologies being tested include blood sugar monitors, i-states (blood analyst) equipment, lensate and remote data capture platforms.
